Balyasny Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Balyasny Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11	Closed	-$418	–	3316
2022 Q4	$418	Sell	11 -30,507	-100%	-$1.05M	﹤0.01%	2714
2022 Q3	$767K	Sell	30,518 -66,080	-68%	-$1.83M	﹤0.01%	1900
2022 Q2	$2.94M	Buy	96,598 +87,481	+960%	+$2.61M	0.01%	1206
2022 Q1	$299K	Sell	9,117 -135,404	-94%	-$4.02M	﹤0.01%	1925
2021 Q4	$3.81M	Buy	+144,521	New	+$11.2M	0.01%	944
2021 Q2	–	Sell	-108,809	Closed	-$10.8M	–	2489
2021 Q1	$10.8M	Buy	+108,809	New	+$12.7M	0.05%	461
2020 Q4	–	Sell	-5,284	Closed	-$515K	–	1805
2020 Q3	$515K	Buy	+5,284	New	+$660K	﹤0.01%	1100
2020 Q2	–	Sell	-3,895	Closed	-$562K	–	1581
2020 Q1	$562K	Buy	+3,895	New	+$752K	0.01%	880

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's RETA Position: Q1 2023 in Review

Balyasny Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 11 shares — an estimated $418 sold.

Balyasny Asset Management first reported a position in RETA in Q1 2020 and held it in 8 quarters. The position peaked at $10.8M in Q1 2021. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Balyasny Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Balyasny Asset Management sold 11 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $418.
Balyasny Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 8 quarters.
Balyasny Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.8M in Q1 2021.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.